Seed Therapeutics
Private Company
Funding information not available
Overview
SEED Therapeutics is a private, pre-revenue biotech developing a next-generation platform for molecular glue degraders. Its core innovation, the RITE3™ platform, seeks to unlock the full universe of over 600 human E3 ligases to rationally degrade disease proteins considered 'undruggable' by traditional modalities. The company has a lead oncology asset, ST-01156, in Phase 1 trials and a pipeline of partnered and internal programs, backed by a scientifically distinguished founding team including Nobel Laureate Avram Hershko. SEED represents a high-potential, high-risk venture aiming to expand the reach of targeted protein degradation beyond the current limitations of the field.
Technology Platform
RITE3™ platform for the rational identification of novel E3 ligase-target pairs and the de novo discovery of molecular glue degraders, leveraging access to over 600 human E3 ligases.
Opportunities
Risk Factors
Competitive Landscape
SEED operates in the competitive targeted protein degradation field, competing against public TPD specialists like Arvinas, Nurix, and Kymera Therapeutics, as well as internal efforts at large pharmaceutical companies. Its key differentiation is the explicit focus on expanding the universe of usable E3 ligases, moving beyond the field's current reliance on cereblon and VHL.